Early Detection.
Early detection and treatment is the key to maintaining a lifetime of healthy vision for your patients. Diopsys® ERG (electroretinography) vision tests provide you with objective, functional information on the performance of retinal ganglion cells. These test results help you identify “stressed” cells at a subclinical stage, when the cells have become dysfunctional but are still alive.1 By starting treatment at this early stage, before evident structural defects, you can help extend your patients’ sight.
- Objectively measure functional loss and recovery2
- Enhanced treatment tracking and disease management
- Clear, intuitive report interpretation
Pattern Electroretinography (ERG) Vision Testing
ERG has been recognized as an effective test in helping to diagnose and manage disease including, Glaucoma, Age-Related Macular Degeneration (AMD), and Diabetic Edema, among others.3 4 5 Clinical Support for pattern ERG testing comes from leading eye care institutions including the American Academy of Ophthalmology, Bascom Palmer Eye Institute, and Wills Eye Hospital.3 6 7
Resources
Expand sections to view resources.
There are no resources of this type for this product.
- Ventura LM, Sorokac N, De Los Santos R, Feuer WJ, Porciatti V. The Relationship between Retinal Ganglion Cell Function and Retinal Nerve Fiber Thickness in Early Glaucoma. Invest Ophthalmol Vis Sci. 2006;47:3904–3911.
- Ventura et al. Progressive loss of retinal ganglion cell function is hindered with IOP-lowering treatment in early glaucoma. Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):659-63
- Banitt et al. Progressive Loss of Retinal Ganglion Cell Function Precedes Structural Loss by Several Years in Glaucoma Suspects. IOVS, March 2013, Vol. 54, No. 3 (From the Bascom Palmer Eye Institute, supported by Grant National Institutes Health–National Eye Institute (NIH-NEI), NIH Center Grant, and Research to Prevent Blindness)
- Oner et al. Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Doc Ophthalmol. 2009 Aug;119(1):37-42. doi: 10.1007/s10633-009-9167-8.
- Ozkiris A. Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema. Doc Ophthalmol 2010;120:243-50.
- Chapter 4. Section: The Glaucoma Suspect. 2015-2016 edition of the AAO Basic and Clinical Science Course on Glaucoma
- 2. Resende A. et al. Repeatability of Steady-State Pattern Electroretinogram and Full-Field Electroretinogram using a novel office-based testing platform in normal subjects. Invest Ophthalmol Vis Sci. September 2016, Vol.57, 3949.
Pattern ERG is a technology that allows us to have earlier diagnosis or confirmation of glaucoma than anything else that we currently use.
